Skip to content

A study of nosogenesis and treatment of Upper gastrointestinal functional gastrointestinal disorders

A study of nosogenesis and treatment of Upper gastrointestinal functional gastrointestinal disorders

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009429
Enrollment
Unknown
Registered
2016-10-15
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper gastrointestinal functional gastrointestinal disorders

Interventions

control group : Esomeprazole
Traditional Chinese medicine treatment group :xiangbin prescription
Integrated group:Esomeprazole+xiangbin prescription

Sponsors

Guangdong Province Hospital of Traditional Chinese Medical
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with non erosive gastroesophageal reflux diseases meet the Gastric prolapse and Diagnostic criteria; 2. The patients who had not been treated with the gastric prolapse in the first 2 weeks before manometry; 3. The patients not be treated by PPI or Prokinetic drugs in past one week before the trial; 4. Duration of the disease more than 6 months; 5. the patient easy to make sense the treatment protocol and cooperating with the doctors; 6. Aged 18-65 years old; 7. Signed informed consent and willingness to cooperate with inspectors.

Exclusion criteria

Exclusion criteria: 1. Complicated with the primary and secondary upper gastrointestinal tract and other organs, tissues and malignant lesions; 2. Complicated with digestive tract malformation or the patients had a Gastrointestinal surgery history; 3. Woman in the period of pregnant or lactating; 4. Patients complicated with serious mental illness; 5. Patients complicated with diabetes mellitus, hyperthyroidism, and connective tissue disease; 6. Complicated with severe heart, liver and kidney dysfunction, endocrine and hematopoietic system diseases; 7. Patients complicated with the severe primary smooth muscle disease that can not take care of themselves; 8. The patients who are currently attending or participating in other clinical studies in past one month; 9. The researchers considers who is not suitable for this clinical study.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal Qality of Life Index;24 hours pH dynamic acid determination;Gastric antrum - pyloro duodenal manometry;

Secondary

MeasureTime frame
hamilton Anxiety Scale;Hamilton Depression Scale;Ghrelin;motilin;Corticotropin releasing hormone;Bradykinin;

Countries

China

Contacts

Public ContactShang Wenfan

Guangdong Province Hospital of Traditional Chinese Medical

gzswf@126.com+86 13922125318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026